RepliCel Life Sciences Inc.
2020 - 401 West Georgia Street V6B 5A1 Vancouver, BC, Canada

This weekend was Canadian Thanksgiving. We're thankful we had to work this weekend on getting closer to a potential deal that would bring us a great strategic partner in an important market and some critical capital. #nopromises #sayyourprayers #fingerscrossed #begrateful

Emerging from pandemic shutdowns, we're pleased with how investors are responding to our current financing. Given obligations regarding our outstanding audit and filings, we closed an early tranche this week but we're not done. Watch for a shareholder update coming soon. https://t.co/SC4tBWaFac

We're very proud our technology got a "what I'm most excited about" mention from Jerry Shapiro in a wide-ranging and informative interview today on all-things-related-to-hair-loss treatments by the wonderful Doris Day, MD. https://lnkd.in/gB_adaV (see about the 40min mark) #hairloss #androgenicalopecia #shiseido #alopecia #celltherapy #regenerativemedicine

Despite the global crisis, RepliCel has had a run of positive developments. Just before our collaborating labs at the University of British Columbia and University of Victoria temporarily closed, we saw a glimpse of very promising data from the NSERC-funded project with Dr. Mohsen Akbari at the UVic's Laboratory for Innovations in MicroEngineering. We eagerly await their safe return to work and resumption of what is potentially a very valuable development project.

RepliCel offers positive news in troubled times. https://zcu.io/zM4H

PRESS RELEASE - Publication of Clinical Data Confirms RepliCel’s Treatment for Androgenic Alopecia Effective in Men and Women https://zcu.io/YPLk

Shiseido is committed to continuing to invest in RCH-01 (licensed, for Asia, from RepliCel) as a treatment for male and female-pattern hair loss. See a recent update to the research page on their website here: https://corp.shiseido.com/en/rd/development/newresearch.html

Japan's Regulatory Agency, PMDA, Clears RepliCel Life Sciences to Proceed to Final Consultation for Tendon and Skin Cell Therapy Products RepliCel completes the second of three formal consultation reviews with Japan's Pharmaceuticals and Medical Devices Agency in its application to obtain clearance to proceed with two clinical studies "This provides a clear signal to Japanese investors, clinicians, and strategic partners with whom we are in discussions, that we are delivering... on our ‘First-in-Japan’ strategy which aims to have four products on the market in Japan by 2023. http://bit.ly/2vdDnBX

Japan's Patent Office issues RepliCel two new patents for its regenerative medicine technologies. The granting of these two patents for large-market clinical applications is key to RepliCel's first-in-Japan strategy announced March 2019. http://bit.ly/335uarS

Late last week, an article was published in the prestigious JAAD summarizing positive data from a clinical study of RCH-01 at Japan's Tokyo Medical University and Toho University Ohashi Medical Center. The product was manufactured / supplied by Shiseido (RepliCel's licensee in Asia). We are very pleased that the data in the randomized, placebo-controlled, double-blinded clinical study of 65 patients (male and female) with pattern hair loss confirms the observations from our p...h 1 trial but in a larger cohort , in female patients, and against a placebo-control. ______ Autologous Cell-Based Therapy for Male and Female Pattern Hair Loss using Dermal Sheath Cup Cells: A Randomized Placebo-Controlled Double-Blinded Dose Finding Clinical Study https://www.jaad.org/article/S0190-9622(20)30272-3/pdf

PRESS RELEASE - Commercial-Grade Replicel Injectors RepliCel in Production https://zurl.co/DeV0

Happy New Year! A lot has happened at RepliCel in the past few months. To find out more, check out our New Year's newsletter. https://zurl.co/bKHt

Check out the latest article from the desk of our CEO: A New Year of Gratitude and Promise https://www.linkedin.com//new-year-gratitude-promise-lee-b

PRESS RELEASE - RepliCel Announces its Incoming Board of Directors https://zurl.co/wskd